UBE2S promotes malignant properties via VHL/HIF‐1α and VHL/JAK2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma
Abstract Background Ubiquitin‐conjugating enzyme E2S (UBE2S), an E2 enzyme, is associated with the development of various tumors and exerts oncogenic activities. UBE2S is overexpressed in tumors, including hepatocellular carcinoma (HCC). However, the key molecular mechanisms of UBE2S in HCC still ne...
Main Authors: | Junyi Wu, Xiangjie Xu, Shasha Wu, Weiwei Shi, Guang Zhang, Yin Cao, Zhongxia Wang, Junhua Wu, Chunping Jiang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-09-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.6431 |
Similar Items
-
The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma
by: Song Peng, et al.
Published: (2020-11-01) -
VHL-P138R and VHL-L163R Novel Variants: Mechanisms of VHL Pathogenicity Involving HIF-Dependent and HIF-Independent Actions
by: Cecilia Mathó, et al.
Published: (2022-03-01) -
The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis
by: Petra Hudler, et al.
Published: (2022-02-01) -
Ubiquitin Pathway in VHL Cancer Syndrome
by: Michael Ohh
Published: (2006-08-01) -
Identification of 3 novel <it>VHL</it> germ-line mutations in Danish VHL patients
by: Dandanell Mette, et al.
Published: (2012-07-01)